A novel bispecific antibody, ivonescimab, has demonstrated significant potential in treating squamous non-small-cell lung cancer, according to new data from the Harmoni-6 Phase 3 trial. The study, which focused on patients in China, revealed that the drug reduced the risk of death by 34% when administered alongside chemotherapy. Patients receiving this combination experienced a median […]